EZH2 upregulation has been described in varying cardiac diseases, including in heart tissue from patients with end-stage dilated cardiomyopathy [83], in atrial muscle and atrial fibroblasts from patients with atrial fibrillation (marked by significant atrial fibrosis and atrial fibroblast differentiation) [84], and in serum from patients with coronary heart disease [85]. Here, EZH2 is linked to heart disorder.